Evidence map›Paper›PMID 37736365›Full record

ArticlePediatric investigation2023

Rapid response with good toleration of sirolimus for life-threatening neonatal lymphatic malformations.

Shixiao Dong, Li Li, Jiaosheng Xu, Zhonglong Han, Xia Zheng

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shixiao DongDepartment of Neonatology, Neonatal Center, Beijing Children's Hospital Capital Medical University, National Center for Children's Health Beijing China.
Li LiDepartment of Dermatology, Plastic Surgery Hospital Chinese Academy of Medical Sciences Beijing China.
Jiaosheng XuDepartment of Dermatology, Beijing Children's Hospital Capital Medical University, National Center for Children's Health Beijing China.ORCID https://orcid.org/0000-0001-9880-2383
Zhonglong HanDepartment of Radiology, Beijing Children's Hospital Capital Medical University, National Center for Children's Health Beijing China.
Xia ZhengDepartment of Neonatology, Neonatal Center, Beijing Children's Hospital Capital Medical University, National Center for Children's Health Beijing China.
Capital Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lymphatic malformations (LMs) are rare vascular anomalies predominantly affecting infants, which can be debilitating or life-threatening when complicated with intralesional bleeding or infection. Effective and safe management strategies are essential in such cases. Case presentation: We report a case series involving four Chinese neonates with life-threatening LMs, initially treated with oral sirolimus. All patients achieved rapid relief and sustained remission, using a lower sirolimus dosage than previously recommended. Furthermore, adverse events were rarely recorded during follow-up. Conclusion: Sirolimus can be considered a promising choice for neonates with intricate and life-threatening LMs. Initiation with a reduced sirolimus dose is advisable.

Indexed as

DosageLymphatic malformationsNeonatesSirolimus

Identifiers

PMID37736365
PMCPMC10509387
OpenAlexW4386332152

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.